Platelet inhibition with orodispersible ticagrelor in acute coronary syndromes according to morphine use: the TASTER study final results

• Published in: European heart journal. Cardiovascular pharmacotherapy 2023-12, Vol.9 (8), p.692-700
• Main Authors: Parodi, Guido, Dossi, Filippo, Raccis, Mario, Talanas, Giuseppe, Mura, Enrico, Siciliano, Roberta, Guarino, Simona, Marini, Alessandro, Franca, Paolo, Saba, Pier Sergio, Sanna, Giuseppe D, Canonico, Mario E
• Format: Article
• Language: English
• Subjects: Acute Coronary Syndrome - diagnosis; Acute Coronary Syndrome - drug therapy; Adenosine - adverse effects; Aggregation; Bivalirudin; Blood platelets; Cardiac patients; Comparative analysis; Coronary heart disease; Fondaparinux; Humans; Morphine; Morphine Derivatives; Percutaneous Coronary Intervention - adverse effects; Percutaneous Coronary Intervention - methods; Platelet Aggregation Inhibitors - adverse effects; Tablets; Ticagrelor - adverse effects; Transluminal angioplasty
• ISSN: 2055-6837; 2055-6845
• DOI: 10.1093/ehjcvp/pvad061

Abstract Aim To date, it is still unknown whether orodispersible tablet (ODT) ticagrelor might represent a suitable way to reach a proper antiaggregation in acute coronary syndrome (ACS) patients receiving morphine. Aim of the present study was to evaluate platelet inhibition with 180 mg ticagrelor loading dose (LD) administered as ODT compared with standard coated tablet ticagrelor formulation in ACS patients undergoing percutaneous coronary intervention (PCI) according to morphine use. Methods and Results One-hundred and 30 patients presenting with STEMI or very high-risk NSTE-ACS were randomly assigned to receive ODT or standard ticagrelor LD. Potential morphine-ticagrelor interaction was assessed by stratified randomization according to morphine use. Platelet reactivity was evaluated by Platelet Reactivity Units (PRU) VerifyNow™ 1, 2, 4, and 6 h after ticagrelor LD. The primary endpoint was residual platelet reactivity 1 h after LD across the two ticagrelor formulation and according to morphine use. Safety endpoints were major bleedings and other in-hospital ticagrelor administration-related adverse events. One hour after LD, PRU median value was higher in morphine-treated patients (N = 32) as compared with patients not receiving morphine (N = 98; PRU = 187 [70–217]) vs. 73 [7–187]; P = 0.012). In patients with morphine, 1-h PRU values were similar between study groups (192 [114–236] vs. 173 [16–215] in ODT and standard tablet ticagrelor, respectively). Similarly, in patients without morphine, 1-h PRU values were not significantly different between study groups (69 [8–152] vs. 110 [6—193] in ODT and standard tablet ticagrelor, respectively). Platelet reactivity appeared similar in the 2 study arms at 2, 4, and 6 h after LD. No significant difference was observed among patients with or without morphine regarding in-hospital adverse events or drug side-effects, even if a reinfarction due to acute stent thrombosis was observed in a patient treated with morphine. Conclusions There was no difference between ODT and standard ticagrelor tablets in terms of post-LD residual platelet reactivity, percentage of platelet inhibition or safety regardless to morphine use. Graphical Abstract Graphical Abstract Patients with acute myocardial infarction were randomized in 1:1 arm in ODS vs. STD ticagrelor. Potential morphine-ticagrelor interaction was assessed by stratified randomization according to morphine use. Platelet reactivity units was assessed by VerifyNow at b